Healthy Volunteers
Conditions
Brief summary
The main goals of this study are: 1) To assess the relative bioavailability of a single oral dose of 400 mg maribavir commercial (marketed) tablet formulation administered with a low-fat/low-calorie meal relative to administration under fasting conditions. 2) To assess the relative bioavailability of a single oral dose of 400 mg maribavir commercial (marketed) tablet formulation administered with a high-fat/high calorie meal relative to administration under fasting conditions. A single dose of 400 mg maribavir (commercial \[marketed\] tablet formulation) will be administered orally under 3 different feeding conditions: 1. Fasting (Treatment A), 2. Fed following a low-fat/low-calorie meal (Treatment B), and 3. Fed following a high fat/high-calorie meal (Treatment C). There will be a washout period of a minimum of 72 hours between each single dose of investigational drug (ID) administration on Day 1 in each treatment cycle of 3 days. Pharmacokinetic samples will be collected at pre-dose and up to 36 hours post-dose in each treatment period. Safety and tolerability will be assessed throughout the study by Treatment Emergent Adverse Events (TEAEs), vital signs, electrocardiograms (ECGs), and clinical laboratory evaluations.
Interventions
DRUGMaribavir
Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Sponsors
Takeda Development Center Americas, Inc.
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Participants must fulfill the following inclusion criteria before the first dose of the Investigational drug (ID) to be eligible for participation in the study: * An understanding, ability, and willingness to fully comply with study procedures and restrictions and ability to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent * Age 19-55 years, inclusive at the time of consent, at the screening visit. * Male, or non-pregnant, non-breastfeeding female who agrees to comply with any applicable contraceptive requirements of the protocol or female of non-childbearing potential. * Healthy as determined by the Investigator or designee on the basis of screening evaluations and medical history. * Hemoglobin for males greater than or equal to (\>=) 135.0 gram per liter (g/L) and females \>=120.0 g/L at the screening visit and on Day 1 of Treatment Period 1. * Body mass index (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2), inclusive with a body weight greater than (\>) 50 kilogram (kg) (110 pound \[lbs\]), at the screening visit. * Ability to swallow a dose of the ID.
Exclusion criteria
Participants must not be enrolled in the study if they meet any of the following criteria before the first dose of the ID: * History or presence of gastritis, Gastrointestinal (GI) tract, hepatic disorder or cholecystectomy, history of treated or untreated Helicobacter pylori, ulcer disease or other clinical GI condition and history of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gall bladder removal, or current recurrent disease that could affect the action, absorption, or disposition of the ID, or clinical or laboratory assessments. * Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the ID or procedures. * Known or suspected intolerance or hypersensitivity to the ID, closely related compounds, or any of the stated ingredients and excipients. * Significant illness, as judged by the Investigator or designee, within 2 weeks of the first dose of the ID. * Has diarrhea within 4 hours of the first dose of the ID. * Donors of blood or blood products (e.g., plasma or platelets) within 60 days prior to receiving the first dose of the ID. * Within 30 days prior to the first dose of the ID: * Have used any investigational product (if elimination half-life is less than \[\<\] 6 days, otherwise 5 half-lives). * Have been enrolled in a clinical study (including vaccine studies) that may impact this study. * Have had any substantial changes in eating habits. * Systolic blood pressure \>140 millimeters of mercury (mmHg) or \<90 mmHg, and diastolic blood pressure \>90 mmHg or \<50 mmHg, at the screening visit. * Twelve-lead ECG with corrected QT interval (QTc) \>450 millisecond (msec) at the screening visit. * Known history of alcohol or other substance abuse within the last year. * Male participants who consume more than 21 units of alcohol per week or 3 units per day. Female participants who consume more than 14 units of alcohol per week or 2 units per day. * A positive screen for alcohol or drugs of abuse at the screening visit or on Day -1 of Treatment Period 1. * A positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen at the screening visit. * Use of tobacco in any form or other nicotine-containing products in any form. Ex-users must self-report that they have stopped using tobacco for at least 3 months prior to receiving the first dose of the ID. * Routine consumption of more than 2 units of caffeine per day or participants who experience caffeine withdrawal headaches. Decaffeinated coffee, tea, or cola are not considered to contain caffeine. * Current use of any prescription medication with the exception of hormonal contraceptives and hormonal replacement therapy. * Current use of antacids, proton pump inhibitors, or H2 antagonists within 14 days of the first dose of the ID. * Inability or unwillingness to consume 100 percent of high-fat meal or low-fat meal (including participants with lactose or gluten intolerance). * Recent history (within 1 month) of oral/nasal cavity infections, history of gastroesophageal reflux, asthma treatment with albuterol, or zinc supplementation. * Participants with dry mouth syndrome or burning mouth syndrome or participants suffering from dysgeusia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Maribavir | Day 1: Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose | Cmax of maribavir in plasma was reported using the non-compartmental analysis. |
| Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Maribavir | Day 1: Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose | AUClast of maribavir in plasma was reported using the non-compartmental analysis. |
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of Maribavir | Day 1: Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose | AUC0-infinity of maribavir in plasma was reported using the non-compartmental analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs | From start of study drug administration to follow-up (up to Day 18) | TEAEs were defined as adverse events (AEs) with a start date on or after the first dose of the ID, or with a start date before the date of first dose of the ID but increasing in severity after the first dose of the ID. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality or birth defect, an important medical event. Any clinically significant changes from baseline in vital signs, electrocardiograms (ECGs), and clinical laboratory results were reported as TEAEs. Number of participants who experienced at least one TEAEs and serious TEAE were reported. |
| Number of Participants Based on Severity of TEAEs | From start of study drug administration to follow-up (up to Day 18) | Severity of TEAEs were determined by following criteria: Mild: An AE that was usually transient and might require only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living; Moderate: An AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but possessed no significant or permanent risk of harm to the research participant; Severe: An AE that interrupted usual activities of daily living, or significantly affects clinical status, or might require intensive therapeutic intervention. Number of participants based on severity of TEAEs as assessed by the Investigator were reported. |
| Number of Participants Based on Causality of TEAEs | From start of study drug administration to follow-up (up to Day 18) | The causality relationship of each AE to the ID was assessed using the following categories: Related: An AE that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship was at least a reasonable possibility, that was, the relationship could not be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, might also be responsible; Not Related: An AE that did not follow a reasonable temporal sequence from administration of a drug and/or that could reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments. Number of participants based on causality of TEAEs as assessed by the Investigator were reported. |
Countries
United States
Participant flow
Recruitment details
This study was conducted at single center in the United States from 25 May 2022 to 02 July 2022.
Pre-assignment details
A total of 31 healthy participants were enrolled in this 3-period crossover study and were randomized to 1 of 6 treatment sequences to receive maribavir 400 milligrams (mg) tablet in fasting state (Treatment A), fed following a low-fat/low-calorie meal (Treatment B) or fed following a high-fat/high-calorie meal (Treatment C).
Participants by arm
| Arm | Count |
|---|---|
| Sequence 1: Treatment A + Treatment B + Treatment C Participants received maribavir single 400 mg tablet, on Day 1 of Treatment Period 1 under fasting condition (Treatment A), followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 2 administered with a low fat/low calorie meal (Treatment B), and further followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal (Treatment C). A washout period of minimum of 72 hours between each investigational drug (ID) dosing was maintained. | 5 |
| Sequence 2: Treatment A + Treatment C + Treatment B Participants received maribavir single 400 mg tablet, on Day 1 of Treatment Period 1 under fasting condition (Treatment A), followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal (Treatment C), and followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 3 administered with a low fat/low calorie meal (Treatment B). A washout period of minimum of 72 hours between each ID dosing was maintained. | 6 |
| Sequence 3: Treatment B + Treatment A + Treatment C Participants received maribavir single 400 mg tablet, on Day 1 of Treatment Period 1 administered with a low fat/low calorie meal (Treatment B), followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 2 under fasting condition (Treatment A), and followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal (Treatment C). A washout period of minimum of 72 hours between each ID dosing was maintained. | 5 |
| Sequence 4: Treatment B + Treatment C + Treatment A Participants received maribavir single 400 mg tablet, on Day 1 of Treatment Period 1 administered with a low fat/low calorie meal (Treatment B), followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal (Treatment C), and followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 3 under fasting condition (Treatment A). A washout period of minimum of 72 hours between each ID dosing was maintained. | 5 |
| Sequence 5: Treatment C + Treatment A + Treatment B Participants received maribavir single 400 mg tablet, on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 2 under fasting condition (Treatment A), and followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 3 administered with a low fat/low calorie meal (Treatment B). A washout period of minimum of 72 hours between each ID dosing was maintained. | 5 |
| Sequence 6: Treatment C + Treatment B + Treatment A Participants received maribavir single 400 mg tablet, on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 2 administered with a low fat/low calorie meal (Treatment B), and followed by maribavir single 400 mg tablet, on Day 1 of Treatment Period 3 under fasting condition (Treatment A). A washout period of minimum of 72 hours between each ID dosing was maintained. | 5 |
| Total | 31 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Period 2 (2 Days) | Adverse Event | 0 | 1 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Sequence 6: Treatment C + Treatment B + Treatment A | Sequence 1: Treatment A + Treatment B + Treatment C | Sequence 2: Treatment A + Treatment C + Treatment B | Sequence 3: Treatment B + Treatment A + Treatment C | Sequence 4: Treatment B + Treatment C + Treatment A | Sequence 5: Treatment C + Treatment A + Treatment B | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 42.8 years STANDARD_DEVIATION 10.26 | 27.8 years STANDARD_DEVIATION 5.02 | 37.7 years STANDARD_DEVIATION 6.35 | 26.0 years STANDARD_DEVIATION 5.61 | 37.2 years STANDARD_DEVIATION 11.48 | 39.2 years STANDARD_DEVIATION 7.92 | 35.2 years STANDARD_DEVIATION 9.57 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 5 Participants | 4 Participants | 5 Participants | 5 Participants | 5 Participants | 29 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 4 Participants | 3 Participants | 5 Participants | 1 Participants | 3 Participants | 17 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 1 Participants | 3 Participants | 0 Participants | 4 Participants | 2 Participants | 14 Participants |
| Sex: Female, Male Female | 2 Participants | 2 Participants | 1 Participants | 2 Participants | 2 Participants | 1 Participants | 10 Participants |
| Sex: Female, Male Male | 3 Participants | 3 Participants | 5 Participants | 3 Participants | 3 Participants | 4 Participants | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 31 | 0 / 30 | 0 / 31 |
| other Total, other adverse events | 7 / 31 | 9 / 30 | 7 / 31 |
| serious Total, serious adverse events | 0 / 31 | 0 / 30 | 0 / 31 |
Outcome results
Primary
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of Maribavir
AUC0-infinity of maribavir in plasma was reported using the non-compartmental analysis.
Time frame: Day 1: Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose
Population: The PK set included all participants who received at least 1 dose of maribavir, did not vomit or had diarrhea within 4 hours of the ID dosing, and had 5 or more post-dose time points with evaluable post-dose maribavir concentration values.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Maribavir 400 mg | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of Maribavir | 106 mcg*hr/mL | Geometric Coefficient of Variation 29.6 |
| Treatment B: Maribavir 400 mg | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of Maribavir | 88.7 mcg*hr/mL | Geometric Coefficient of Variation 34.3 |
| Treatment C: Maribavir 400 mg | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of Maribavir | 93.2 mcg*hr/mL | Geometric Coefficient of Variation 33.4 |
90% CI: [81.28, 88.34]
90% CI: [84.3, 91.53]
Primary
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Maribavir
AUClast of maribavir in plasma was reported using the non-compartmental analysis.
Time frame: Day 1: Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose
Population: The PK set included all participants who received at least 1 dose of maribavir, did not vomit or had diarrhea within 4 hours of the ID dosing, and had 5 or more post-dose time points with evaluable post-dose maribavir concentration values.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Maribavir 400 mg | Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Maribavir | 103 microgram*hour per milliliter(mcg*hr/mL) | Geometric Coefficient of Variation 30 |
| Treatment B: Maribavir 400 mg | Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Maribavir | 85.6 microgram*hour per milliliter(mcg*hr/mL) | Geometric Coefficient of Variation 34 |
| Treatment C: Maribavir 400 mg | Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Maribavir | 90.0 microgram*hour per milliliter(mcg*hr/mL) | Geometric Coefficient of Variation 33.2 |
90% CI: [80.74, 87.66]
90% CI: [83.87, 90.96]
Primary
Maximum Observed Plasma Concentration (Cmax) of Maribavir
Cmax of maribavir in plasma was reported using the non-compartmental analysis.
Time frame: Day 1: Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose
Population: The pharmacokinetic (PK) set included all participants who received at least 1 dose of maribavir, did not vomit or had diarrhea within 4 hours of the ID dosing, and had 5 or more post-dose time points with evaluable post-dose maribavir concentration values.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Treatment A: Maribavir 400 mg | Maximum Observed Plasma Concentration (Cmax) of Maribavir | 17.8 microgram per milliliter (mcg/mL) | Geometric Coefficient of Variation 28.9 |
| Treatment B: Maribavir 400 mg | Maximum Observed Plasma Concentration (Cmax) of Maribavir | 13.4 microgram per milliliter (mcg/mL) | Geometric Coefficient of Variation 23.3 |
| Treatment C: Maribavir 400 mg | Maximum Observed Plasma Concentration (Cmax) of Maribavir | 12.7 microgram per milliliter (mcg/mL) | Geometric Coefficient of Variation 21 |
90% CI: [71.78, 81.78]
90% CI: [67.14, 76.37]
Secondary
Number of Participants Based on Causality of TEAEs
The causality relationship of each AE to the ID was assessed using the following categories: Related: An AE that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship was at least a reasonable possibility, that was, the relationship could not be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, might also be responsible; Not Related: An AE that did not follow a reasonable temporal sequence from administration of a drug and/or that could reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments. Number of participants based on causality of TEAEs as assessed by the Investigator were reported.
Time frame: From start of study drug administration to follow-up (up to Day 18)
Population: The safety set included all participants who received at least 1 dose of maribavir.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment A: Maribavir 400 mg | Number of Participants Based on Causality of TEAEs | Not Related TEAEs | 3 Participants |
| Treatment A: Maribavir 400 mg | Number of Participants Based on Causality of TEAEs | Related TEAEs | 8 Participants |
| Treatment B: Maribavir 400 mg | Number of Participants Based on Causality of TEAEs | Related TEAEs | 9 Participants |
| Treatment B: Maribavir 400 mg | Number of Participants Based on Causality of TEAEs | Not Related TEAEs | 1 Participants |
| Treatment C: Maribavir 400 mg | Number of Participants Based on Causality of TEAEs | Not Related TEAEs | 0 Participants |
| Treatment C: Maribavir 400 mg | Number of Participants Based on Causality of TEAEs | Related TEAEs | 7 Participants |
Secondary
Number of Participants Based on Severity of TEAEs
Severity of TEAEs were determined by following criteria: Mild: An AE that was usually transient and might require only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living; Moderate: An AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but possessed no significant or permanent risk of harm to the research participant; Severe: An AE that interrupted usual activities of daily living, or significantly affects clinical status, or might require intensive therapeutic intervention. Number of participants based on severity of TEAEs as assessed by the Investigator were reported.
Time frame: From start of study drug administration to follow-up (up to Day 18)
Population: The safety set included all participants who received at least 1 dose of maribavir.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment A: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Mild | 11 Participants |
| Treatment A: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Severe | 0 Participants |
| Treatment A: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Moderate | 0 Participants |
| Treatment B: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Mild | 10 Participants |
| Treatment B: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Moderate | 0 Participants |
| Treatment B: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Severe | 0 Participants |
| Treatment C: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Mild | 7 Participants |
| Treatment C: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Severe | 0 Participants |
| Treatment C: Maribavir 400 mg | Number of Participants Based on Severity of TEAEs | Moderate | 0 Participants |
Secondary
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs
TEAEs were defined as adverse events (AEs) with a start date on or after the first dose of the ID, or with a start date before the date of first dose of the ID but increasing in severity after the first dose of the ID. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality or birth defect, an important medical event. Any clinically significant changes from baseline in vital signs, electrocardiograms (ECGs), and clinical laboratory results were reported as TEAEs. Number of participants who experienced at least one TEAEs and serious TEAE were reported.
Time frame: From start of study drug administration to follow-up (up to Day 18)
Population: The safety set included all participants who received at least 1 dose of maribavir.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment A: Maribavir 400 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs | TEAEs | 11 Participants |
| Treatment A: Maribavir 400 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs | Serious TEAEs | 0 Participants |
| Treatment B: Maribavir 400 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs | TEAEs | 10 Participants |
| Treatment B: Maribavir 400 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs | Serious TEAEs | 0 Participants |
| Treatment C: Maribavir 400 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs | TEAEs | 7 Participants |
| Treatment C: Maribavir 400 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs | Serious TEAEs | 0 Participants |